BRPI0814529A2 - Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central. - Google Patents

Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.

Info

Publication number
BRPI0814529A2
BRPI0814529A2 BRPI0814529-6A2A BRPI0814529A BRPI0814529A2 BR PI0814529 A2 BRPI0814529 A2 BR PI0814529A2 BR PI0814529 A BRPI0814529 A BR PI0814529A BR PI0814529 A2 BRPI0814529 A2 BR PI0814529A2
Authority
BR
Brazil
Prior art keywords
alfa2c
ilmetil
dihydrobenzo
dioxin
antagonists
Prior art date
Application number
BRPI0814529-6A2A
Other languages
English (en)
Inventor
David Din Belle
Patrik Holm
Arto Karljalainen
Arto Tolvanen
Gerd Wohlfahrt
Petteri Rummakko
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39884455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0814529(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of BRPI0814529A2 publication Critical patent/BRPI0814529A2/pt
Publication of BRPI0814529B1 publication Critical patent/BRPI0814529B1/pt
Publication of BRPI0814529B8 publication Critical patent/BRPI0814529B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0814529A 2007-07-20 2008-07-18 derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas de alfa2c para uso no tratamento de doenças do sistema nervoso periférico e central BRPI0814529B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95098307P 2007-07-20 2007-07-20
US60/950,983 2007-07-20
PCT/FI2008/000090 WO2009013390A1 (en) 2007-07-20 2008-07-18 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases

Publications (3)

Publication Number Publication Date
BRPI0814529A2 true BRPI0814529A2 (pt) 2015-01-27
BRPI0814529B1 BRPI0814529B1 (pt) 2019-09-17
BRPI0814529B8 BRPI0814529B8 (pt) 2021-05-25

Family

ID=39884455

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814529A BRPI0814529B8 (pt) 2007-07-20 2008-07-18 derivados de 2,3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas de alfa2c para uso no tratamento de doenças do sistema nervoso periférico e central

Country Status (31)

Country Link
US (3) US8492549B2 (pt)
EP (1) EP2176252B1 (pt)
JP (1) JP5460590B2 (pt)
KR (1) KR101535059B1 (pt)
CN (1) CN101842369B (pt)
AR (1) AR069271A1 (pt)
AU (1) AU2008278924B2 (pt)
BR (1) BRPI0814529B8 (pt)
CA (1) CA2693804C (pt)
CL (1) CL2008002114A1 (pt)
CO (1) CO6331473A2 (pt)
CY (1) CY1115789T1 (pt)
DK (1) DK2176252T3 (pt)
EA (1) EA017554B1 (pt)
ES (1) ES2502215T3 (pt)
GE (1) GEP20125538B (pt)
HR (1) HRP20141156T1 (pt)
IL (1) IL202964A (pt)
MA (1) MA31521B1 (pt)
MY (1) MY153872A (pt)
NZ (1) NZ582432A (pt)
PE (1) PE20090890A1 (pt)
PL (1) PL2176252T3 (pt)
PT (1) PT2176252E (pt)
RS (1) RS53571B1 (pt)
SI (1) SI2176252T1 (pt)
TN (1) TN2010000029A1 (pt)
TW (1) TWI457122B (pt)
UA (1) UA100695C2 (pt)
WO (1) WO2009013390A1 (pt)
ZA (1) ZA201000314B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
KR20100135325A (ko) * 2008-04-29 2010-12-24 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 조절제
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
AU2009242095A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
US8822679B2 (en) * 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US9518034B2 (en) 2013-10-14 2016-12-13 California Institute Of Technology Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CN108774274B (zh) * 2015-03-06 2020-11-03 北京大学 唾液酸甲酯甲苷衍生物及其合成方法和应用
CA2981041C (en) 2015-03-27 2023-09-05 California Institute Of Technology Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst
TWI704145B (zh) * 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
US10040784B2 (en) 2016-03-11 2018-08-07 California Institute Of Technology Compositions and methods for acylating lactams
KR20190020343A (ko) 2016-06-29 2019-02-28 오리온 코포레이션 벤조디옥산 유도체 및 이의 약제학적 용도
JP7376358B2 (ja) * 2017-03-12 2023-11-08 ワン，シャオドン オピオイド受容体調節因子としての多環式アミン
US10358422B2 (en) 2017-11-01 2019-07-23 California Institute Of Technology Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
GB201801130D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
AU2019350264B2 (en) * 2018-09-25 2025-01-23 Bayer Aktiengesellschaft α2-Adrenoceptor subtype C (alpha-2C) antagonists for the treatment of sleep apnea
EP3699173A1 (en) 2018-10-18 2020-08-26 California Institute of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
CN118785902A (zh) 2022-01-07 2024-10-15 拜耳公司 用于治疗睡眠呼吸暂停的α2-肾上腺素受体亚型C拮抗剂
KR102776660B1 (ko) * 2022-01-25 2025-03-04 재단법인 한국파스퇴르연구소 벤조다이옥세인 유도체 화합물 및 이의 의약 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) * 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US3647790A (en) * 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
GB1411531A (en) * 1972-10-24 1975-10-29 Lafon Labor Amino derivatives of 1,4-benzodioxan
JPS5163193A (ja) 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US4039676A (en) * 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
HU181575B (en) 1980-10-03 1983-10-28 Richter Gedeon Vegyeszet Process for preparing 3-chloro-propyl-malonic acid ester and cyano-acetic acid ester derivatives
FR2525600A1 (fr) * 1982-04-21 1983-10-28 Bouchara Emile Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
DD250930A1 (de) 1986-06-08 1987-10-28 Isis Chemie Zwickau Veb Verfahren zur herstellung neuer tetrahydroisochinolinderivate
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
KR900701774A (ko) 1988-08-16 1990-12-04 제임스 제이. 플린 살진균성 벤조디옥산 아민 유도체
CA2104873C (en) 1991-02-26 2000-05-23 James N. Campbell Compositions and methods of treatment of sympathetically maintained pain
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
FR2744451B1 (fr) * 1996-02-01 1998-04-24 Pf Medicament Nouvelles imidazolidinones, pyrimidinones, et 1,3-diazepin-2 -ones, leur preparation et leurs applications en therapeutique
HUP0003362A3 (en) 1997-05-06 2001-04-28 Novo Nordisk As Piperidine derivatives and pharmaceutical compositions containing them
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
PT1036065E (pt) 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
AU9087301A (en) * 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
MXPA04009601A (es) 2002-04-03 2004-12-13 Orion Corp Compuestos policiclicos como potentes antagonistas del adreno-receptor alfa-2.
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
JP5163193B2 (ja) 2008-03-13 2013-03-13 セイコーエプソン株式会社 プリンタシステム及びプリンタシステムにおける制御方法

Also Published As

Publication number Publication date
US20120035210A9 (en) 2012-02-09
WO2009013390A1 (en) 2009-01-29
DK2176252T3 (en) 2014-12-08
MA31521B1 (fr) 2010-07-01
IL202964A (en) 2013-12-31
US8492549B2 (en) 2013-07-23
HRP20141156T1 (hr) 2015-01-16
EP2176252A1 (en) 2010-04-21
CN101842369A (zh) 2010-09-22
KR101535059B1 (ko) 2015-07-24
RS53571B1 (sr) 2015-02-27
US20140179926A1 (en) 2014-06-26
JP5460590B2 (ja) 2014-04-02
CA2693804A1 (en) 2009-01-29
ES2502215T3 (es) 2014-10-03
US8809536B2 (en) 2014-08-19
AU2008278924B2 (en) 2013-09-26
TN2010000029A1 (en) 2011-09-26
GEP20125538B (en) 2012-05-25
AU2008278924A1 (en) 2009-01-29
TW200908961A (en) 2009-03-01
CA2693804C (en) 2015-11-24
CY1115789T1 (el) 2017-01-25
CN101842369B (zh) 2014-01-22
US20100216836A1 (en) 2010-08-26
CL2008002114A1 (es) 2009-04-03
JP2010534197A (ja) 2010-11-04
PT2176252E (pt) 2014-12-03
NZ582432A (en) 2012-03-30
ZA201000314B (en) 2010-10-27
KR20100044220A (ko) 2010-04-29
EA201070169A1 (ru) 2010-06-30
US8697723B2 (en) 2014-04-15
BRPI0814529B1 (pt) 2019-09-17
BRPI0814529B8 (pt) 2021-05-25
AR069271A1 (es) 2010-01-13
PL2176252T3 (pl) 2015-04-30
US20130281486A1 (en) 2013-10-24
TWI457122B (zh) 2014-10-21
EP2176252B1 (en) 2014-09-03
PE20090890A1 (es) 2009-07-08
SI2176252T1 (sl) 2014-12-31
HK1148530A1 (en) 2011-09-09
UA100695C2 (ru) 2013-01-25
EA017554B1 (ru) 2013-01-30
MY153872A (en) 2015-03-31
CO6331473A2 (es) 2011-10-20

Similar Documents

Publication Publication Date Title
BRPI0814529A2 (pt) Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0812889A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal.
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
BRPI1009252A2 (pt) composto, pró-droga, composição farmacêutica, métodos para prevenir ou tratar doenças do sistema nervoso central, e mal de alzheimer, e, uso do composto ou de uma pró-droga do mesmo
BRPI0821440A2 (pt) Derivados de tetra-hidro-imidazo[1,5-a] pirazina, processo de preparação e uso medicinal dos mesmos
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BR112012001344A2 (pt) derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
CL2008001025A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
IL192009A0 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
BRPI0812740A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
BRPI0818690A2 (pt) Derivados de quinazolinediona, sua preparação e seus usos terapêuticos.
CL2008001493A1 (es) Compuesto derivado de 3-(imidazolil)-pirazolo[3,4-b]piridina; procedimiento de prepararcion de dicho compuesto; y su uso para tratar inflamacion, trastornos inmunorregulatorios, entre otros.
IL203206A (en) 2-Amino Derivatives, 4-Amido Quinazoline, Drugs Containing and Using Theirs, and Process for Manufacturing
BRPI0818841A2 (pt) Compostos para uso em formação de imagem, diagnóstico e/ou tratamento de doenças do sistema nervoso central ou de tumores
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
CL2012001483A1 (es) Compuestos derivados de 3,6-diazabiciclo[3.1.1]heptanos, como ligandos de receptores nicotinicos neuronales de acetilcolina; composicion farmaceutica; y su uso para el tratamiento o la prevencion de demencia presenil, alzheimer, esquizofrenia, dolor agudo o cronico, entre otras enfermedades.
CL2008001563A1 (es) Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras.
DK1773796T3 (da) Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
BRPI0821431A8 (pt) derivados de oxindol substituídos e o seu uso para o tratamento de doenças dependentes de vasopressina.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF